Table 3.
The risk for CHD between patients with pSS and control group in Cox proportional hazard regression modelling.
| Model 1* | Model 2# | |||||
|---|---|---|---|---|---|---|
| aHR* | 95% C.I. | p value | aHR* | 95% C.I. | p value | |
| Sjögren’s syndrome | 1.24 | 1.10–1.40 | 0.0005 | 1.17 | 1.03–1.34 | 0.0140 |
| Age (per 1 year) | 1.04 | 1.04–1.04 | <0.0001 | 1.04 | 1.04–1.04 | <0.0001 |
| Sex (reference: Female) | ||||||
| Male | 1.14 | 1.01–1.28 | 0.0327 | 1.15 | 1.02–1.29 | 0.0218 |
| Co-morbidities | ||||||
| Diabetes mellitus | 1.16 | 1.01–1.34 | 0.0371 | 1.15 | 0.93–1.41 | 0.1956 |
| Hypertension | 1.70 | 1.51–1.92 | <0.0001 | 1.55 | 1.32–1.82 | <0.0001 |
| Hyperlipidaemia | 1.38 | 1.21–1.57 | <0.0001 | 1.39 | 1.21–1.59 | <0.0001 |
| COPD | 1.32 | 1.16–1.50 | <0.0001 | 1.27 | 1.11–1.44 | 0.0003 |
| Stroke | 1.07 | 0.86–1.31 | 0.5522 | 0.98 | 0.79–1.22 | 0.8705 |
| Chronic kidney disease | 1.17 | 0.93–1.48 | 0.1818 | 1.17 | 0.92–1.48 | 0.1952 |
| Chronic liver diseases | 1.21 | 1.03–1.42 | 0.0175 | 1.19 | 1.02–1.4 | 0.0294 |
| Cancer | 0.98 | 0.77–1.25 | 0.8759 | 0.98 | 0.77–1.24 | 0.8606 |
| Medications | ||||||
| Antihyperglycemic drugs | 0.99 | 0.78–1.26 | 0.9428 | |||
| Antihypertensive drugs | 1.07 | 0.91–1.26 | 0.3934 | |||
| Statin | 0.86 | 0.69–1.06 | 0.1604 | |||
| Corticosteroids (oral) | 1.20 | 0.97–1.49 | 0.0963 | |||
| NSAID | 1.26 | 1.11–1.43 | 0.0004 | |||
| DMARDs$ | 1.00 | 0.73–1.35 | 0.9786 | |||
| Aspirin | 1.45 | 1.20–1.74 | <.0001 | |||
| PPI | 0.96 | 0.68–1.35 | 0.7963 | |||
| H2 Receptor | 1.15 | 0.92–1.43 | 0.2191 | |||
aHR, adjusted hazard ratio; C.I, confidence interval; COPD, chronic obstructive pulmonary disease; DMARDs, disease-modifying antirheumatic drugs; NSAID, nonsteroidal antiinflammatory drugs; PPI, proton pump inhibitors.
*In model 1, aHRs were adjusted for age, sex, and co-morbidities. #In model 2, aHRs were adjusted for age, sex, co-morbidities, and medications.
$DMARDs, including Hydroxychloroquine, Methotrexate, Sulfasalazine.